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ABSTRACT 
Background: Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are used for 
coronary revascularization in patients with multivessel and left main (LM) coronary artery disease. Stroke is 
amongst the most feared outcomes after revascularization. As it occurs infrequently, studies with large 
numbers of patients are required to detect differences in stroke rates between CABG and PCI. 
Methods: We performed a collaborative individual patient-level pooled analysis of 11 randomized clinical trials 
comparing CABG with PCI using stents; ERACI II (n=450), ARTS (n=1205), MASS II (n=408), SoS (n=988), SYNTAX 
(n=1800), PRECOMBAT (n=600), FREEDOM (n=1900), VA CARDS (n=198), BEST (n=880), NOBLE (n=1184) and 
EXCEL (n=1905). Thirty-day and 5-year stroke events were compared between CABG and PCI using a random 
effects Cox proportional hazards model, stratified by trial. The impact of stroke on 5-year mortality was 
explored.  
Results: The analysis included 11,518 patients randomly assigned to CABG (n=5765) or PCI (n=5753) with a 
mean follow-up of 3.8 ± 1.4 years during which a total of 293 strokes occurred. At 30 days, the rate of stroke 
was 1.1% after CABG and 0.4% after PCI (P<0.001). At 5-year follow-up, stroke remained significantly higher 
after CABG than after PCI (3.2% versus 2.6%, P=0.027). Rates of stroke between 30 days and 5 year were 
comparable: 2.1% after CABG versus 2.2% after PCI (P=0.72). Treatment effect of PCI versus CABG on 5-year 
stroke was not modified by using bare-metal stents or drug-eluting stents, the coronary complexity, or by 
clinical characteristics except for a significant interaction among diabetics (CABG: 4.9% versus PCI: 2.6%) and 
non-diabetics (CABG: 2.4% versus PCI: 2.6%) (Pint=0.004). Patients who suffered a stroke versus those without a 
stroke within 30 days of the procedure had a high 5-year mortality after CABG (41.5% versus 8.9%, P<0.001) 
and PCI (45.7% versus 11.1%, P<0.001). 
Conclusions: In this large-scale individual patient-level pooled analysis, CABG resulted in significantly higher 30-
day and 5-year rates of stroke than PCI, but rates of stroke between 30 days and 5 years were similar. Five-year 
mortality was higher for patients suffering a stroke within 30 days of the CABG or PCI procedure. 
Keywords: Coronary artery bypass grafting; CABG; Percutaneous coronary intervention; PCI; Stenting; Left 
main; Multivessel; Stroke 
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INTRODUCTION 
Coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) are 
treatment options for patients with coronary artery disease who require coronary 
revascularization. Numerous randomized clinical trials have compared these two treatments; 
first in the era of balloon angioplasty, subsequently with the use of bare-metal stents (BMS) (1, 
2), and most recently with use of drug-eluting stents (DES) (3). With improving technology and 
techniques of PCI, trials have increasingly focused on more complex patients with three-vessel 
disease (3VD), left main (LM) disease, and diabetes. 
A pooled analysis of individual data from 10 randomized trials showed that CABG, as 
compared with PCI using balloon angioplasty or BMS, had similar long-term rates of mortality, 
but higher complication rates at 90 days after the procedure (1). Several studies suggest that 
CABG is associated with a significant increase of procedural stroke, a devastating outcome with 
substantial mortality, morbidity and reduced quality of life. It is uncertain whether advances in 
PCI and CABG have led to a decrease in the number of strokes, but since stroke occurs 
infrequently, individual randomized trials do not have enough power to detect meaningful small 
differences between PCI and CABG. Moreover, it is unclear to what degree long-term survival is 
impacted by the occurrence of stroke (4). 
We performed a collaborative analysis with individual patient data from 11 randomized 
clinical trials of patients with multivessel or LM coronary artery disease who were randomly 
assigned to CABG or PCI to compare procedural and long-term rates of stroke and the impact of 
stroke on survival. 
 
METHODS 
Study Selection and Data Collection 
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On the 19th of July, 2017, the PubMed, Embase, and Cochrane databases were searched without 
limits to identify randomized clinical trials comparing CABG with PCI for the treatment of 
multivessel or LM coronary artery disease. The search was performed with the following 
combination of keywords: “coronary artery bypass”, “percutaneous coronary intervention”, 
“stent” and “random*”. Reference lists of retrieved articles were also hand-searched. 
Conference abstracts were not considered. 
 Studies were selected if (i) patients were randomly assigned to undergo CABG or PCI 
treatment, (ii) patients had multivessel or left main coronary artery disease, (iii) patients did not 
present with a myocardial infarction, (iv) PCI was performed using stents (BMS or DES) and not 
balloon angioplasty, (v) the occurrence of stroke was collected beyond 30 days of follow-up, and 
(vi) more than one-year follow-up for all-cause mortality was available. 
 After study selection, principal investigators were contacted and invited to supply data 
for a collaborative, pooled analysis based on individual patient data. Participating studies 
completed a prespecified spreadsheet that included baseline characteristics and outcome 
measures (Supplementary Appendix 1). The provided data were cross-checked against the 
primary publication and longer-term follow-up publications from each individual trial, and 
inconsistencies were resolved by contacting trial principal investigators. Investigators from 11 
individual trials provided the data for the current pooled analysis: ERACI II (5), ARTS (6), MASS-II 
(7), SoS (8), SYNTAX (9), PRECOMBAT (10), FREEDOM (11), VA CARDS (12), BEST (13), EXCEL (14), 
and NOBLE (15). Only the data from the LE MANS trial (n=105) could not be obtained (16). Baseline 
and procedural characteristics of individual trials are presented in Supplementary Appendix 2.  
Local Medical Ethics Committees approved all these trials at the time of study execution. 
Patients in each of the 11 trials provided written informed consent. 
 
Outcomes and Follow-up 
6 
 
Follow-up time was calculated from the time of the procedure. Follow-up time was calculated 
from randomization if patients suffered a stroke or died before the procedure took place or if 
patients did not undergo revascularization but only received medical treatment. The primary 
endpoint of this study was stroke. A procedural stroke occurred during the first 30 days after the 
procedure. All trials, but the SoS trial, collected stroke during the entire duration of follow-up; 
the SoS trial collected stroke only up to 1 year after revascularization (8). The definition of stroke 
was a focal neurological deficit of central origin lasting more than 24 hours either confirmed by 
neuroimaging or a deficit lasting longer than 72 hours without the need for confirmation with 
neuroimaging. The secondary endpoint of this study was all-cause death. In all trials, a Clinical 
Events Committee (CEC) adjudicated the events.  
 
Statistical Analysis 
The main analyses were performed according to the intention-to-treat principle. Outcome data 
were also analyzed on an as-treated basis to determine more accurately the impact of the 
specific procedure on stroke rate. Continuous variables are expressed as a mean ± standard 
deviation and compared using t-tests, and discrete data are presented as frequencies and 
compared using chi-square tests. We pooled the individual patient data from 11 trials to provide 
descriptive statistics and unadjusted Kaplan-Meier survival curves. Hazard ratios of CABG versus 
PCI for stroke were estimated using a Cox proportional hazards model that was stratified by trial, 
using a gamma frailty term to account for heterogeneity among trials. Frailties are unobserved 
factors, distributed as 𝛾 random variables with a mean of 1 and variance 𝜗. Hence, the variance 
of the frailty terms represents heterogeneity in baseline risk among trials. The statistical 
significance of the variance parameter was assessed using the likelihood ratio test. The rate of 
stroke was estimated at 30 days and 5 years, and landmark analyses were performed after 30 
days follow-up to assess the long-term risk of stroke after CABG versus PCI. Since several trials 
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enrolled patients with specific characteristics, subgroup analyses were performed according to 
diabetes status and multivessel or LM disease. The impact of baseline characteristics on 
treatment estimates of 5-year stroke was also explored in subgroup analyses with P-values for 
interaction calculated in a Cox proportional hazards model. Moreover, the impact of off-pump 
CABG as opposed to on-pump CABG was explored among trials that provided information on the 
use of cardiopulmonary bypass. Multivariable Cox proportional hazards models that included 
baseline and procedural characteristics were constructed to predict 30-day and 5-year stroke. 
Variables were included in the multivariable model if P<0.15 at univariable analyses, with the 
variable CABG versus PCI being forced into the model. The impact of stroke within 30 days of the 
procedure on mortality was explored using the Kaplan-Meier method comparing patients with 
and without 30-day stroke. A two-sided P<0.05 was considered to indicate statistical 
significance. All statistical analyses were performed using SPSS software, version 21 (IBM 
Corporation, Armonk, NY, USA) or R software version 3.2.4 (Institute for Statistics and 
Mathematics of WU, Wien, Austria). 
 
Role of the Funding Source 
While several of the individual studies were funded by industry, this collaborative analysis had 
no external funding, and did not involve any of the original study sponsors. The corresponding 
author had full access to the data. The entire group of investigators decided to submit the 
manuscript, which was executed by the corresponding author, who takes final responsibility for 
the content. 
 
RESULTS 
Study Population 
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Eleven trials randomized 11,518 patients; 5765 patients were randomly assigned to CABG and 5753 
to PCI. Of the 5765 patients assigned to CABG, 5421 underwent CABG (94%), 233 underwent PCI 
(4%), and 111 underwent neither procedure (2%). Of the 5753 patients assigned to PCI, 5610 
underwent PCI (98%), 101 underwent CABG (2%), and 42 underwent neither procedure (1%). In the 
as-treated analysis 5522 patients underwent CABG and 5843 patients underwent PCI. Data on cross-
overs in each study are presented in Supplementary Appendix 3. 
Patient enrollment was conducted between 1995 and 2015. PCI was performed in four trials 
exclusively with bare-metal stents (MASS 2, ERACI 2, SoS, and ARTS; n=1518 PCI patients), in three 
trials with first-generation drug-eluting stents (PRECOMBAT, SYNTAX, and FREEDOM; n=2156 PCI 
patients), in three trials with second-generation drug-eluting stents (BEST, EXCEL, and NOBLE; 
n=1978 PCI patients), and in one trial with a mix of stent generations (VA CARDS; n=101 PCI patients). 
There were no clinically significant differences in baseline characteristics between patients 
randomly assigned to CABG and PCI (Table 1). The pooled patient population had a mean age of 63.6 
± 9.8 years and 24% were female. Diabetes was present in 38% of patients, with 12% on insulin. Left 
main disease was present in 39% of patients. At discharge, antiplatelet therapy was prescribed 
significantly more often after PCI than after CABG (P<0.001 for all analyses). 
 The mean follow-up was 3.8 ± 1.4 years, with follow-up among survivors being 4.0 ± 1.3 
years.  
 
Stroke 
A total of 293 strokes occurred during follow-up. The cumulative stroke rate at 5-year follow-up was 
3.2% (n=164) in patients randomized to CABG and 2.6% (n=129) in patients randomized to PCI 
(P=0.027) (Figure 1A). At 30 days, stroke occurred in 64 patients (1.1%) randomized to CABG and in 
21 patients (0.4%) randomized to PCI (P<0.001) (Figure 1B). The rate of stroke after 30 days up to 5 
years was comparable between CABG (2.1%; n=100) and PCI (2.2%; n=108) (P=0.72) (Figure 1B). 
Results were similar in the as-treated analysis. The value of the frailty parameter theta (θ) for 
9 
 
heterogeneity was θ=0.09 (P<0.001). In a multivariable analysis, the only independent predictor of 
30-day stroke was CABG as a method of revascularization (HR=8.33, 95% CI 1.06-62.5; P=0.043). In 
multivariable analysis of 5-year stroke, CABG versus PCI failed to be an independent predictor. 
 Within the 7 trials that provided data on on- or off-pump CABG (n=3945), 28% of patients 
underwent off-pump CABG surgery. Rates of stroke at 30 days were 0.6% [6/1085] after off-pump 
and 1.4% [40/2860] after on-pump CABG (P=0.13), with 5-year rates of 2.9% [25/1085] versus 3.5% 
[84/2860], respectively (P=0.60). After CABG, 44% of patients were discharged on dual antiplatelet 
therapy. The rate of stroke at 5 years was comparable between patients on DAPT or single 
antiplatelet therapy (3.1% [48/1759] versus 3.8% [67/2109], respectively; P=0.84). 
 Whether PCI was performed with BMS or DES did not have an impact on the rate of stroke at 
5 years (2.6% [39/1518] versus 2.7% [90/4235], P=0.83). When analyzing BMS and DES trials 
separately, the difference between PCI and CABG was similar among trials that used exclusively BMS 
(2.6% versus 3.2% after CABG, P=0.39) or DES (2.7% versus 3.3% after CABG, P=0.038). Only 190 
patients were discharged on single antiplatelet therapy after PCI. The rates of stroke at 5 years were 
2.5% (91/4384) for patients on DAPT and 4.0% (5/190) for patients on single antiplatelet therapy 
(P=0.41). 
 
Subgroup Analyses 
Analyses of patients with LM disease showed that there was no difference in the 5-year rate of stroke 
between CABG and PCI (2.6% [51/2245] versus 2.6% [43/2233], respectively; P=0.36). In patients 
with multivessel disease, the rate of stroke was significantly higher after CABG than after PCI (3.6% 
[n=113/3520] versus 2.7% [86/3520], respectively; P=0.039). There was no significant interaction 
between the treatment effect of CABG versus PCI and baseline characteristics for the occurrence of 
5-year stroke, except for diabetes (Figures 2 and 3). The difference in stroke was significantly higher 
in diabetic patients randomized to CABG versus PCI (4.9% [n=86/2171] versus 2.6% [n=47/2215], 
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respectively; P<0.001) but not in non-diabetics (2.4% [n=78/3594] versus 2.6% [n=82/3538], 
respectively; P=0.78) (P for interaction = 0.004)(Figure 2). 
 
Impact of Stroke on Death 
A total of 976 deaths occurred during follow-up. Patients who suffered a stroke within 30 days after 
CABG had significantly higher 5-year mortality compared to patients that did not suffer a stroke 
within 30 days of CABG (41.5% [23/64] versus 8.9% [414/5701]; P<0.001). Mortality was also 
significantly higher in PCI patients that suffered a stroke within 30 days versus those who did not 
(45.7% [9/21] versus 11.1% [530/5732], respectively; P<0.001). Mortality among patients that 
suffered a stroke any time during follow-up is depicted in Figure 4.  
 
DISCUSSION 
In this individual patient-level pooled analysis with data from 11 randomized clinical trials comparing 
CABG with PCI for multivessel or left main coronary artery disease, CABG resulted in significantly 
higher rates of 5-year stroke. This was driven by a higher rate of stroke in the first 30 days after the 
procedure. However, rates of stroke between 30 days and 5-year follow-up were similar between 
CABG and PCI. Strokes occurring within 30 days after the procedure significantly increased mortality, 
with a rate approaching 50% at 5 years. 
 Procedural strokes are more common after CABG for several reasons. First, most CABG 
procedures are performed with some extend of aortic manipulation (17-19). Data from cohort 
studies suggests that limiting, if not completely avoiding aortic manipulation reduces stroke rates 
substantially (20). The use of bilateral internal mammary arteries (BIMA) avoids the need for 
proximal anastomoses and side-clamping of the aorta and has therefore been associated with lower 
stroke rates (21). In the current analysis the rate of BIMA use was low. Second, strategies to reduce 
postoperative bleeding that are often required after CABG but not PCI, such as usage of tranexamic 
acid, lead to a hypercoagulable state that potentially increase the risk of seizures and stroke (22). 
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Another reason might be postoperative atrial fibrillation that is frequent after CABG and increases 
the risk of stroke in the early postoperative period (23). Fourth, periods of hypoperfusion during 
surgery and low cardiac output syndrome in the early postoperative period may impair brain 
perfusion, leading to ischaemia and watershed strokes (24). Another hypothesis is that strokes are 
lower after PCI due to dual antiplatelet therapy immediately after stent implantation, while CABG 
patients generally only receive single antiplatelet therapy (25).  
Our landmark analysis demonstrated a low rate of stroke beyond 30 days that was similar 
between CABG and PCI. The need for more repeat revascularizations after PCI than after CABG, as 
shown in these individual trials (26), did not result in a higher stroke rate after PCI. Moreover, our 
subgroup analyses demonstrate no significant heterogeneity according to baseline characteristics; 
therefore, PCI produces superior results to CABG in terms of 5-year stroke rates among diverse 
patients. 
It remains unclear whether there is a difference in the severity of stroke occurring after CABG 
and PCI. In the FREEDOM trial, severely disabling strokes accounted for 55% and 27% of all strokes 
occurring after CABG and PCI, respectively (11). An in-depth analysis of strokes occurring in the 
SYNTAX trial showed that 68% and 47% in the CABG and PCI groups, respectively, had residual 
deficits at discharge (27). It is evident that quality of life of patients that suffered a stroke is impaired, 
although no studies have compared quality of life of patients suffering a stroke after CABG or PCI to 
determine whether the higher rate of residual deficits after CABG is translated into significantly 
lower long-term quality of life. We did, however, find that 5-year mortality was significantly higher 
among patients that suffered a 30-day stroke versus those that did not suffer a stroke.  
Sharing of trial data among investigators is crucial to assess safety and efficacy in small 
patient subgroups (28). This collaborative analysis from 11 randomized clinical trials demonstrates 
that a pooled analysis is required to analyze events that occur infrequently, such as stroke. 
Moreover, the inclusion of patients from different geographic areas increases the external validity of 
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our results. All trials prospectively enrolled patients and had a CEC adjudicating events, confirming 
the diagnosis of stroke.  
Our analysis also has some limitations. First, techniques for both CABG and PCI have evolved 
during the patient inclusion period that ranged from 1995 to 2015. Although we showed consistent 
stroke rates after PCI with DES and BMS and for off-pump and on-pump CABG, it is unclear whether 
other unmeasured factors may have played a role. Secondly, there was some heterogeneity in 
baseline characteristics among trials, which may have been caused by more recent trials focusing on 
patients with more complex coronary artery disease or with diabetes. Third, no data on the severity 
of stroke or on residual deficits after stroke could be pooled because only two trials collected such 
data and definitions varied. Fourth, antiplatelet therapy may reduce stroke incidences, but we lacked 
data of medication regimens during follow-up. Nevertheless, most patients receive at least one 
antiplatelet agent after CABG or PCI, which should be sufficient for stroke prevention. 
 
CONCLUSION 
In this individual patient-level pooled analysis of randomized trials including patients with multivessel 
or left main coronary artery disease who require coronary revascularization, CABG resulted in 
significantly higher 30-day and 5-year rates of stroke than PCI, but rates of stroke after 30 days up to 
5 years were similar. Five-year mortality was high in patients suffering a stroke within 30 days after 
CABG and PCI.
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TABLES 
Table 1. Baseline, procedural, and discharge data of randomized cohorts. 
Characteristic PCI (n=5753) CABG (n=5765) 
Age 
 
63.6 ± 9.8 (5753) 63.7 ± 9.9 (5765) 
Female gender 23.9% (1373/5753) 23.8% (1371/5765) 
BMI>30 
 
28.1% (1548/5506) 28.3% (1558/5511) 
Smoking current 22.3% (1274/5701) 22.3% (1273/5703) 
Diabetes 
 
38.5% (2215/5753) 37.7% (2171/5765) 
 On Insulin 12.9% (545/4234) 11.9% (504/4245) 
Hypertension 67.6% (3880/5739) 68.1% (3913/5748) 
Hypercholesterolemia 69.5% (3982/5726) 67.3% (3862/5735) 
Peripheral vascular disease 8.2% (424/5158) 8.5% (440/5164) 
Carotid artery disease 7.8% (161/2072) 8.1% (168/2074) 
Previous TIA or CVA 5.4% (218/4052) 6.2% (253/4054) 
Previous MI 28.0% (1438/5138) 27.5% (1417/5156) 
LV dysfunction (<30%) 0.9% (49/5303) 1.0% (54/5430) 
Unstable disease 34.6% (1786/5158) 34.2% (1767/5160) 
Three-vessel disease 58.6% (2460/4201) 60.1% (2594/4197) 
Left main disease 38.8% (2233/5753) 38.9% (2245/5765) 
SYNTAX score 24.5 ± 9.0 (4099) 24.7 ± 9.3 (4069) 
PCI – DES used 73.5% (4121/5607) - 
PCI – number of stents 3.1 ± 2.0 (4935) - 
CABG – LIMA use - 96.2% (4574/4753) 
CABG – BIMA use - 18.7% (771/4122) 
CABG – off-pump - 27.5% (1085/3945) 
Aspirin at discharge 97.3% (4487/4612) 95.5% (3814/3994) 
Thienopyridine at discharge 96.7% (4479/4630) 45.1% (1815/4026) 
DAPT 95.1% (4384/4612) 44.0% (1759/3994) 
Values are present as mean ± SD or n/N (%). PCI, percutaneous coronary intervention; CABG, coronary artery 
bypass grafting; BMI, body mass index; TIA, transitory ischemic attack; CVA, cerebrovascular attack; MI, 
myocardial infarction; LV, left ventricular; DES, drug-eluting stents; LIMA, left internal mammary artery; BIMA, 
bilateral internal mammary artery; DAPT, dual antiplatelet therapy. 
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FIGURE LEGENDS 
Figure 1. Stroke after percutaneous coronary intervention versus coronary artery bypass 
grafting during 5-year follow-up (A) and in landmark analyses of 30-day stroke and stroke 
beyond 30 days (B). P-values are from log-rank test. CABG, coronary artery bypass grafting; 
CI, confidence interval; HR, hazard ratio; PCI, percutaneous coronary intervention 
 
Figure 2. Stroke after percutaneous coronary intervention versus coronary artery bypass 
grafting during 5-year follow-up of patients with and without diabetes mellitus (A) and 
patients with left main or multivessel disease (B). There was significant diabetes-by-
treatment interaction (Pint=0.004), without significant interaction according to LM/MVD 
(Pint=0.68). CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; 
DM, diabetes mellitus; LM, left main disease; MVD, multivessel disease 
 
Figure 3. Stroke after percutaneous coronary intervention versus coronary artery bypass 
grafting during 5-year follow-up in subgroup analyses according to baseline and procedural 
characteristics. BMI, body mass index; BMS, bare-metal stents; CABG, coronary artery 
bypass grafting; DES, drug-eluting stents; DM, diabetes mellitus ; HTA, hypertension 
arterials; HLP, hyperlipidemia; LM, left main disease; LVEF, left ventricular ejection fraction; 
MVD, multivessel disease; PCI, percutaneous coronary intervention; PVD, peripheral vascular 
disease; PMI, prior myocardial infarction; HR, hazard ratio; CI, confidence interval 
 
Figure 4. Death after percutaneous coronary intervention versus coronary artery bypass 
grafting during 5-year follow-up of patients with and without stroke. Solid lines indicate 
patients who developed stroke during follow-up period while dotted lines indicate patients 
without stroke during the 5-year of follow-up. CABG, coronary artery bypass grafting; PCI, 
percutaneous coronary intervention
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FIGURES 
 
Figure 1.  Stroke after percutaneous coronary intervention versus coronary artery bypass grafting during 5-
year follow-up (A) and in landmark analyses of 30-day stroke and stroke beyond 30 days (B). P-values are 
from log-rank test. CABG, coronary artery bypass grafting; CI, confidence interval; HR, hazard ratio; PCI, 
percutaneous coronary intervention 
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Figure 2. Stroke after percutaneous coronary intervention versus coronary artery bypass grafting during 5-
year follow-up of patients with and without diabetes mellitus (A) and patients with left main or multivessel 
disease (B). There was significant diabetes-by-treatment interaction (Pint=0.004), without significant 
interaction according to LM/MVD (Pint=0.68). CABG, coronary artery bypass grafting; PCI, percutaneous 
coronary intervention; DM, diabetes mellitus; LM, left main disease; MVD, multivessel disease 
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Figure 3. Stroke after percutaneous coronary intervention versus coronary artery bypass grafting during 5-
year follow-up in subgroup analyses according to baseline and procedural characteristics. BMI, body mass 
index; BMS, bare-metal stents; CABG, coronary artery bypass grafting; DES, drug-eluting stents; DM, diabetes 
mellitus ; HTA, hypertension arterials; HLP, hyperlipidemia; LM, left main disease; LVEF, left ventricular 
ejection fraction; MVD, multivessel disease; PCI, percutaneous coronary intervention; PVD, peripheral vascular 
disease; PMI, prior myocardial infarction; HR, hazard ratio; CI, confidence interval 
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Figure 4. Death after percutaneous coronary intervention and coronary artery bypass grafting during 5-year 
follow-up of patients with and without stroke. Solid lines indicate patients who developed stroke during 
follow-up period while dotted lines indicate patients without stroke during the 5-year of follow-up. CABG, 
coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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SUPPLEMENTARY MATERIAL 
APPENDIX 1. Data included in the prespecified extraction form. 
Age, gender, body mass index, angina classification, hypertension, hypercholesterolemia, a family 
history of CAD, smoking status, diabetes, renal function, atrial fibrillation, peripheral vascular 
disease, carotid disease, previous transient ischemic attack or stroke, previous myocardial infarction, 
left ventricular function, previous myocardial revascularization, EuroSCORE, number of vessel 
disease, location of coronary lesions, medication use at baseline, treatment by PCI or CABG, 
completeness of revascularization, off-pump CABG, venous conduit use during CABG, internal 
mammary artery use during CABG, number of stents used during PCI, stent type used, postoperative 
hospital stay, postoperative atrial fibrillation, medication use at discharge, death during follow-up, 
stroke during follow-up, and medication use during follow-up. 
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APPENDIX 2. Baseline and procedural characteristics in individual trials. 
 
Characteristic ERACI-II  
(n=450) 
ARTS  
(n=1205) 
MASS-II  
(n=408) 
SoS  
(n=988) 
SYNTAX  
(n=1800) 
PRECOMB
AT 
(n=600) 
FREEDOM 
(n=1900) 
VA CARDS 
(n=198) 
BEST  
(n=880) 
NOBLE  
(n=1184) 
EXCEL 
(n=1905) 
Patient inclusion 1996-1998 1997-1998 1995-2000 1996-1999 2005-2007 2004-
2009 
2005-2010 2006-2010 2008-2013 2008-2015 2010-2014 
Study location Argentina Europe, 
South 
America, 
Australasia 
Brazil Europe, 
Canada 
Europe, US Korea North 
America, 
South 
America, 
Europe, India, 
Australasia 
US Asia Europe North 
America, 
South 
America, 
Europe, India, 
Australasia 
Age 60.7 ± 10.2 60.6 ± 10.8 59.8 ± 9.0 61.4 ± 9.3 65.1 ± 9.7 62.2 ± 9.7 62.1 ± 9.1 62.4 ± 7.2 64.5 ± 9.4 66.2 ± 9.7 65.9 ± 9.6 
Female gender 21% 
(93/450) 
23% 
(283/1205) 
31% 
(125/408) 
21% 
(206/988) 
22% 
(402/1800) 
24% 
(141/600) 
29% 
(544/1900) 
1% (2/198) 29% 
(251/880) 
22% 
(256/1184) 
23% 
(441/1905) 
BMI>30 NA 22% 
(260/1203) 
25% 
(100/408) 
22% 
(220/982) 
32% 
(579/1799) 
3% 
(20/595) 
42% 
(789/1896) 
68% 
(132/195) 
4% (35/880) 29% 
(336/1155) 
34% 
(639/1904) 
Smoking current 52% 
(233/540) 
27% 
(323/1203) 
33% 
(134/408) 
15% 
(149/988) 
21% 
(363/1760) 
29% 
(172/600) 
16% 
(298/1900) 
25% 
(48/195) 
20% 
(177/880) 
20% 
(235/1170) 
22% 
(415/1850) 
Diabetes 17% 
(78/450) 
17% 
(208/1205) 
28% 
(115/408) 
14% 
(142/988) 
25% 
(452/1800) 
32% 
(192/600) 
100% 
(1900/1900) 
100% 
(198/198) 
41% 
(363/880) 
15% 
(184/1184) 
29% 
(554/1905)  
On 
insulin 
NA NA 5% (20/408) 3% (28/988) 10% 
(182/1800) 
3% 
(19/600) 
32% 
(615/1900) 
NA 4% (38/880) NA 8% 
(147/1905) 
Hypertension 71% 
(318/450) 
45% 
(540/1205) 
62% 
(253/408) 
45% 
(447/988) 
75% 
(1349/1787) 
53% 
(317/600) 
85% 
(1612/1900) 
96% 
(187/195) 
67% 
(591/880) 
66% 
(775/1182) 
74% 
(1404/1892) 
Hypercholesterol
emia 
61% 
(275/450) 
58% 
(694/1201) 
73% 
(298/408) 
52% 
(509/988) 
78% 
(1391/1785) 
41% 
(247/600) 
84% 
(1592/1900) 
58% 
(111/191) 
52% 
(461/880) 
80% 
(946/1183) 
70% 
(1320/1875) 
Peripheral 
vascular disease 
23% 
(103/450) 
5% 
(64/1205) 
0% (0/408) 7% (66/988) 10% 
(177/1800) 
4% 
(22/600) 
10% 
(197/1900) 
14% 
(27/195) 
3% (27/880) NA 9% 
(181/1896) 
Carotid artery 
disease 
6% (25/450) NA NA NA 8% 
(148/1800) 
NA NA NA NA NA 8% 
(156/1896) 
Previous 
TIA/stroke 
2% (10/450) NA NA 4% (37/988) 8% 
(150/1788) 
NA 3% (65/1900) 10% 
(20/198) 
8% (70/879) NA 6% 
(119/1903) 
Previous MI 28% 
(126/450) 
43% 
(520/1205) 
47% 
(191/408) 
45% 
(448/988) 
33% 
(585/1780) 
6% 
(33/567) 
26% 
(487/1900) 
42% 
(81/195) 
6% (54/880) NA 17% 
(330/1888) 
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LV dysfunction 
(<30%) 
0% (0/446) 0% (0/1121) 0% (0/408) 1% (4/771) 2% 
(34/1800) 
1% 
(5/542) 
1% (27/1900) 7% (12/177) 1% (5/744) 1% (5/1020) 1% (11/1804) 
Unstable disease 92% 
(412/450) 
36% 
(438/1205) 
0% (0/408) 0% (0/988) 29% 
(513/1800) 
45% 
(272/600) 
31% 
(584/1900) 
NA 44% 
(384/880) 
17% 
(206/1183) 
39% 
(744/1892) 
Number of lesions 2.6 ± 0.6 2.8 ± 1.0 2.8 ± 0.8 2.8 ± 1.1 4.0 ± 1.7 3.0 ± 1.0 NA 3.6 ± 1.5 3.4 ± 1.2 1.7 ± 1.0 NA 
Three-vessel 
disease 
49% 
(220/450) 
33% 
(403/1205) 
58% 
(238/408) 
42% 
(419/988) 
61% 
(1095/1800) 
51% 
(308/600) 
83.4% 
(1573/1887) 
66% 
(120/181) 
77% 
(679/880) 
NA NA 
Left main disease 5% (21/450) 0.1% 
(1/1205) 
0% (0/408) 1% (7/988) 39% 
(705/1800) 
100% 
(600/600) 
0.4% (8/1900) 0% (0/198) 5% (47/880) 100% 
(1184/1184) 
100% 
(1905/1905) 
SYNTAX score NA NA NA NA 28.7 ± 11.4 25.1 ± 
10.0 
26.2 ± 8.6 NA 24.4 ± 7.7 22.0 ± 7.3 20.6 ± 6.2 
PCI – DES used 0% (0/222) 0% (0/593) 0% (0/205) 0% (0/488) 100% 
(885/885) 
100% 
(276/276) 
100% 
(939/939) 
100% 
(93/93) 
100% 
(413/413) 
100% 
(580/580) 
100% 
(935/935) 
PCI – number of 
stents 
1.4 ± 0.6 NA 1.2 ± 0.9 2.6 ± 1.4 4.6 ± 2.3 2.7 ± 1.4 4.1 ± 1.9 NA 3.4 ± 1.4 2.2 ± 1.2 2.4 ± 1.5 
CABG – LIMA use 95% 
(198/209) 
NA 95% 
(188/198) 
93% 
(450/485) 
97% 
(827/854) 
94% 
(233/248) 
94% 
(843/893) 
NA 100% 
(382/382) 
96% 
(545/565) 
99% 
(908/923) 
CABG – BIMA use 0.5% 
(1/209) 
NA 32% 
(65/203) 
10% 
(50/485) 
28% 
(236/854) 
NA 12% 
(110/893) 
NA NA 8% (44/549) 29% 
(265/923) 
CABG – off-pump NA NA NA NA 15% 
(128/854) 
63% 
(155/248) 
18% 
(165/893) 
32% (26/82) 66% 
(252/382) 
16% (88/564) 29% 
(271/923) 
Complete 
revascularization 
68% 
(303/448) 
82% 
(992/1205) 
57% 
(224/408) 
70% 
(693/988) 
60% 
(1043/1741) 
69% 
(416/600) 
90% 
(1701/1900) 
NA 61% 
(518/855) 
94% 
(543/577)* 
NA 
Aspirin at 
discharge 
100% 
(450/450) 
NA 98% 
(391/397) 
NA 92% 
(1633/1766) 
99% 
(593/600) 
98% 
(1826/1867) 
98% 
(172/176) 
97% 
(852/880) 
93% 
(539/580)* 
98% 
(1823/1867) 
Thienopyridine at 
discharge 
53% 
(238/450) 
NA 48% 
(194/408) 
NA 59% 
(1037/1766) 
94% 
(565/600) 
62% 
(1158/1867) 
55% 
(96/176) 
93% 
(818/880) 
97% 
(566/580)* 
66% 
(1227/1867) 
DAPT 53% 
(238/450) 
NA 47% 
(187/397) 
NA 56% 
(987/1766) 
93% 
(560/600) 
81% 
(1513/1867) 
54% 
(94/176) 
92% 
(806/880)  
92% 
(532/580)* 
65% 
(1204/1867) 
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APPENDIX 3. Data on cross-overs in each trial.  
 
Randomized to CABG Randomized to PCI  
Actual 
CABG 
Actual 
PCI 
No 
revasc. 
Actual 
CABG 
Actual 
PCI 
No 
revasc. 
ARTS 579 19 7 6 593 1 
ERACI-II 209 16 0 3 222 0 
MASS-II 198 0 5 6 194 5 
VA-CARDS 81 11 5 6 93 2 
SoS 487 11 2 7 480 1 
FREEDOM 893 18 36 5 939 9 
SYNTAX 854 16 27 11 885 7 
PRECOMBAT 248 51 1 24 276 0 
BEST 382 51 9 19 413 6 
EXCEL 567 23 2 7 580 5 
NOBLE 923 17 17 7 935 6 
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention 
